We are live on ! Find out more
EU

Emory University Portfolio holdings

AUM $160M
1-Year Est. Return 8.57%
This Fund
S&P 500
This Quarter Est. Return
+4.23%
1 Year Est. Return
+8.57%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$153M
AUM Growth
+$2.13M
Cap. Flow
+$1.9M
Cap. Flow %
1.24%
Top 10 Hldgs %
48.62%
Holding
52
New
6
Increased
15
Reduced
19
Closed
6

Top Buys

Rank Stock Value
1
IMMU
Immunomedics Inc
IMMU
+$2.97M
2
SLDB icon
Solid Biosciences
SLDB
+$2.92M
3
MDGL icon
Madrigal Pharmaceuticals
MDGL
+$2.86M
4
TVTX icon
Travere Therapeutics
TVTX
+$2.79M
5
DOVA
Dova Pharmaceuticals, Inc. Common Stock
DOVA
+$2.77M

Top Sells

Rank Stock Value
1
ABMD
Abiomed Inc
ABMD
+$2.89M
2
CORI
Corium International, Inc.
CORI
+$2.2M
3
DRNA
Dicerna Pharmaceuticals, Inc.
DRNA
+$2.2M
4
KALA icon
KALA BIO
KALA
+$2.12M
5
BPMC
Blueprint Medicines
BPMC
+$2.1M

Sector Composition

Rank Sector Weight
1 Healthcare 49.75%
2 Financials 31.55%
3 Consumer Discretionary 7%
4 Industrials 2.82%
5 Communication Services 1.45%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BRK.A icon
1
Berkshire Hathaway Class A
BRK.A
$1.09T
$37.4M 24.5%
117
– –
JD icon
2
JD.com
JD
$39.6B
$10.4M 6.79%
397,578
– –
ACAD icon
3
Acadia Pharmaceuticals
ACAD
$4.89B
$4.08M 2.67%
196,601
+52,476
+36% +$826K
MYOV
4
DELISTED
Myovant Sciences Ltd.
MYOV
$3.37M 2.2%
126,800
+3,745
+3% +$84.8K
GHDX
5
DELISTED
Genomic Health, Inc.
GHDX
$3.36M 2.2%
47,803
-22,667
-32% -$1.33M
SLDB icon
6
Solid Biosciences
SLDB
$974M
$3.29M 2.15%
+4,652
New +$2.92M
ALXN
7
DELISTED
Alexion Pharmaceuticals
ALXN
$3.2M 2.09%
23,015
+934
+4% +$117K
DBVT
8
DBV Technologies
DBVT
$882M
$3.11M 2.04%
13,845
+2,977
+27% +$605K
IFRX icon
9
InflaRx
IFRX
$296M
$3.1M 2.03%
90,437
+12,883
+17% +$416K
BHVN
10
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$2.96M 1.94%
78,838
-11,113
-12% -$409K
NBIX icon
11
Neurocrine Biosciences
NBIX
$15.3B
$2.89M 1.89%
23,485
-5,334
-19% -$605K
ONC
12
BeOne Medicines Ltd
ONC
$40.3B
$2.87M 1.88%
16,642
+2,321
+16% +$390K
ZGNX
13
DELISTED
Zogenix, Inc.
ZGNX
$2.85M 1.86%
57,374
-12,372
-18% -$630K
WVE icon
14
Wave Life Sciences
WVE
$1.02B
$2.82M 1.85%
56,403
-11,522
-17% -$520K
TVTX icon
15
Travere Therapeutics
TVTX
$5.79B
$2.8M 1.83%
+97,510
New +$2.79M
SGEN
16
DELISTED
Seagen Inc. Common Stock
SGEN
$2.76M 1.81%
35,834
-10,900
-23% -$803K
ASND icon
17
Ascendis Pharma A/S
ASND
$16.2B
$2.73M 1.78%
38,486
-2,042
-5% -$141K
INCY icon
18
Incyte
INCY
$24.4B
$2.67M 1.75%
38,637
-1,194
-3% -$82K
ECYT
19
DELISTED
Endocyte, Inc. Common Stock
ECYT
$2.64M 1.73%
148,628
-56,667
-28% -$973K
BMRN icon
20
BioMarin Pharmaceuticals
BMRN
$13.3B
$2.61M 1.71%
26,940
-3,250
-11% -$324K
IMMU
21
DELISTED
Immunomedics Inc
IMMU
$2.61M 1.71%
+125,252
New +$2.97M
MNTA
22
DELISTED
Momenta Pharmaceuticals, Inc.
MNTA
$2.58M 1.69%
+98,084
New +$2.65M
SAGE
23
DELISTED
Sage Therapeutics
SAGE
$2.54M 1.66%
17,998
+2,503
+16% +$386K
FOLD
24
DELISTED
Amicus Therapeutics
FOLD
$2.45M 1.6%
202,726
+20,683
+11% +$289K
MDGL icon
25
Madrigal Pharmaceuticals
MDGL
$11.7B
$2.44M 1.6%
+11,391
New +$2.86M
1
2 3

Similar funds

SGCM
Sanchez Gaunt Capital Management Reno, Nevada $160M AUM
LCA
Legend Capital Advisors New York $160M AUM
SMF
Sterling Manor Financial Saratoga Springs, New York $160M AUM 13.84% 1-Year Est. Return
PCC
Perry Creek Capital New York $160M AUM 3.05% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
RCWM
Royal Capital Wealth Management Carmel, Indiana $161M AUM 18.42% 1-Year Est. Return
BFAG
Blackston Financial Advisory Group The Villages, Florida $160M AUM 16.38% 1-Year Est. Return
SLG
Sanchez Levi Garrett $159M AUM

Emory University's Q3 2018 Portfolio in Review

As of Q3 2018, Emory University held 52 positions worth $153M, up 1.4% from $151M the previous quarter. Its ten largest holdings account for 49% of the portfolio.

Emory University's Q3 2018 filing shows 6 new, 15 increased, 19 reduced and 6 closed positions. Its largest new stake was Immunomedics Inc: 125,252 shares worth $2.61M. The largest sale was Abiomed Inc, an estimated $2.89M.

By sector, the portfolio is most concentrated in Healthcare at 50% of assets, up from 48% a quarter earlier, followed by Financials and Consumer Discretionary.

  • Emory University's largest Q3 2018 buy was Immunomedics Inc: 125,252 shares worth $2.61M.
  • Emory University added most to La Jolla Pharmaceutical Company in Q3 2018, an estimated $897K increase.
  • Emory University's biggest Q3 2018 reduction was Genomic Health, Inc., cutting an estimated $1.33M.
  • Emory University fully exited Abiomed Inc in Q3 2018, selling an estimated $2.89M.
  • Emory University's ten largest holdings make up 49% of its $153M portfolio in Q3 2018.
  • Emory University opened 6 new positions and closed 6 in Q3 2018.
  • Emory University's portfolio value rose 1.4% quarter-over-quarter to $153M.

Based on Emory University's 13F filing for Q3 2018, filed 14 Nov 2018.